How Common Is Breast Cancer? Understanding Its Prevalence, Types, and Treatment

What Is Breast Cancer?

Breast Cancer develops when abnormal cells in breast tissue grow and divide in an uncontrolled way. These cells may form a tumor and, in some cases, spread to nearby tissues, lymph nodes, or distant organs.

Breast cancer is not one single disease. It includes different subtypes that vary according to where the cancer begins, whether it has invaded surrounding tissue, and which biomarkers are present.

Understanding these differences helps healthcare professionals determine the most appropriate diagnostic and treatment approach.

How Common Is Breast Cancer?

Breast cancer prevalence varies by country, age group, population, and the type of breast cancer being measured. Breast cancer primarily affects women, although men can also develop the disease.

Globally, breast cancer is a leading cancer diagnosis among women. The WHO reported approximately 2.3 million new cases in women in 2022, demonstrating the substantial global burden of the disease.

Several factors influence an individual’s likelihood of developing breast cancer, including age, family history, inherited genetic changes, reproductive history, breast density, and certain lifestyle or environmental exposures. Having a risk factor does not mean a person will develop cancer, and some people diagnosed with breast cancer have no known major risk factors.

Types of Breast Cancer

The types of breast cancer can be classified by the cells or structures where the cancer begins and by specific biological characteristics.

Ductal Carcinoma in Situ

Ductal Carcinoma in Situ (DCIS) is a non-invasive breast condition in which abnormal cells are found within the milk ducts. The cells have not invaded through the duct walls into surrounding breast tissue.

DCIS is often detected through screening mammography. Although it is not invasive breast cancer, it may require treatment or monitoring based on its characteristics and the individual’s circumstances.

Invasive Lobular Carcinoma

Invasive lobular carcinoma begins in the lobules, which are the milk-producing glands of the breast. It is called invasive because the cancer cells have spread beyond the lobules into surrounding breast tissue.

This type may present differently from other breast cancers, and its diagnosis may involve imaging, biopsy, and biomarker testing.

Triple-Negative Breast Cancer

Triple-Negative breast cancer is a subtype that lacks three commonly measured receptors: estrogen receptors, progesterone receptors, and excess HER2 protein.

Because it does not rely on these targets in the same way as hormone receptor-positive or HER2-positive cancers, treatment approaches may differ. Chemotherapy, immunotherapy, and other treatments may be considered depending on the stage and individual clinical factors.

HER2-Positive Breast Cancer

HER2-Positive breast cancer contains higher-than-normal levels of the human epidermal growth factor receptor 2 (HER2) protein or gene amplification associated with HER2.

HER2-targeted therapies may be used for eligible patients. Biomarker testing is an important part of determining whether these treatments may be appropriate.

Inflammatory Breast Cancer

Inflammatory breast cancer is a rare and often aggressive form that can cause redness, swelling, warmth, or a peau d’orange appearance of the breast. It may not present as a distinct lump.

Because its symptoms can resemble infection or other breast conditions, persistent changes require prompt medical assessment.

Metastatic Breast Cancer

Metastatic breast cancer is breast cancer that has spread beyond the breast and nearby lymph nodes to distant parts of the body, such as the bones, liver, lungs, or brain.

It is also referred to as stage IV breast cancer. Treatment often focuses on controlling the disease, managing symptoms, maintaining quality of life, and extending survival when possible. Treatment selection depends on the cancer’s subtype, prior therapies, overall health, and other factors.

Fungating Breast Cancer

Fungating breast cancer refers to a breast tumor that has broken through the skin and may result in an open wound. It can cause symptoms such as bleeding, drainage, odor, discomfort, or infection risk.

This presentation requires specialized medical care, including wound management, symptom control, and treatment of the underlying cancer. It is not a separate biological subtype of breast cancer.

Stages of Breast Cancer

The stages of breast cancer describe how extensive the disease is and whether it has spread. Staging helps healthcare professionals understand the cancer and plan treatment.

Breast cancer is commonly described using stages 0 through IV:

• Stage 0: Abnormal cells remain confined to their original location, such as in DCIS.
• Stage I: Cancer is invasive but generally limited to the breast or involves a small amount of nearby tissue.
• Stage II: Cancer may be larger or involve a limited number of nearby lymph nodes.
• Stage III: Cancer is more extensive locally or regionally but has not spread to distant organs.
• Stage IV: Cancer has spread to distant parts of the body and is considered metastatic.

Staging may involve tumor size, lymph node involvement, distant spread, tumor grade, biomarker results, and sometimes multigene testing. The NCI’s breast cancer diagnosis guidance explains how these factors contribute to staging and treatment planning.

How Is Breast Cancer Diagnosed?

Diagnosis may begin with a clinical breast examination, a screening result, or a person noticing a change in the breast.

Depending on the findings, healthcare professionals may recommend:

• Mammography: X-ray imaging used for breast cancer screening and diagnostic evaluation.
• Ultrasound: Imaging that can help assess a lump or abnormal area.
• Breast MRI: An imaging method used in selected situations to provide more detailed information.
• Biopsy: Removal of cells or tissue for examination by a pathologist.

A biopsy is the only definitive way to confirm breast cancer. If cancer is identified, the tissue may also be tested for biomarkers such as estrogen receptors, progesterone receptors, and HER2. These results help guide treatment decisions.

Is Breast Cancer Genetic?

Some breast cancers are associated with inherited genetic changes, but not all breast cancer is hereditary.

Inherited changes in genes such as BRCA1 and BRCA2 can increase the risk of breast and other cancers. A strong family history, diagnosis at a younger age, certain cancer subtypes, or a known familial genetic variant may lead a healthcare professional to recommend genetic counselling or testing.

The NCI notes that approximately 5% to 10% of breast cancers may be associated with inherited pathogenic variants in BRCA1 or BRCA2, although hereditary risk can also involve other genes.

Genetic counselling can help individuals understand what testing may reveal, how results may affect their care, and whether family members could benefit from additional information.

Is Breast Cancer Curable?

The answer depends on the type, stage, biology of the cancer, response to treatment, and other individual factors.

Some breast cancers, particularly those diagnosed at an early stage, can be treated with the goal of eliminating detectable disease. However, doctors may avoid describing every case as permanently cured because recurrence can occur, even after successful treatment.

For metastatic breast cancer, treatment generally focuses on disease control, symptom management, and quality of life. Some people live for many years with metastatic disease, but it is generally considered treatable rather than curable.

A healthcare team can explain prognosis and treatment goals based on the individual’s diagnosis rather than relying on general statistics.

Breast Cancer Treatment Advances

Breast cancer treatment advances have expanded the options available for many patients. Treatment may include one or more of the following:

• Surgery: Procedures such as lumpectomy or mastectomy may be used to remove cancer.
• Radiation therapy: May be recommended to target cancer cells in specific areas.
• Chemotherapy: Uses medicines to destroy or slow the growth of cancer cells.
• Hormone therapy: May be used for hormone receptor-positive breast cancers.
• Targeted therapy: Designed to act on specific cancer-related biomarkers, such as HER2.
• Immunotherapy: May be an option for selected breast cancer subtypes, including certain triple-negative cases.

Treatment plans are individualized. Breast cancer treatment may involve local and systemic therapies, and that the choice depends on the cancer’s type, stage, and biological characteristics.

How to Prevent Breast Cancer?

No strategy can eliminate breast cancer risk entirely, but certain actions may help reduce risk or support earlier detection.

Depending on an individual’s circumstances, risk-reduction and early-detection strategies may include:

• Maintaining regular physical activity
• Discussing alcohol intake and other modifiable risk factors with a healthcare professional
• Understanding personal and family medical history
• Following age- and risk-appropriate breast cancer screening recommendations
• Discussing genetic counselling when family history or other factors suggest increased risk
• Asking a healthcare professional about risk-reducing medication or procedures when appropriate

The NCI’s breast cancer prevention information explains that age, family history, genetics, breast density, reproductive factors, and other exposures can influence risk. It also notes that some interventions may reduce risk for selected individuals.

Is a Breast Cancer Clinical Trial the Right Step for You?

For some patients, participating in research may be an option to discuss with their healthcare team. Is breast cancer clinical trial right step for you totally depends on the study’s eligibility criteria, the patient’s diagnosis, available treatment options, and personal preferences.

Ongoing Research Studies continue to investigate ways to improve diagnosis, treatment, supportive care, and outcomes across different breast cancer subtypes. People interested in breast cancer clinical trials at NHO Revive can explore study information.

Clinical trials may evaluate new medicines, treatment combinations, diagnostic tools, supportive-care approaches, or ways to improve existing treatments. Participation is voluntary, and joining a study does not guarantee a particular outcome.

Final Thoughts

Breast cancer is a significant global health concern, but it is not one uniform disease. Its types, stages, biological features, and treatment responses can vary widely. Understanding risk factors, recognizing potential symptoms, following appropriate screening guidance, and seeking timely medical evaluation can help people make informed healthcare decisions.

Advances in diagnosis, targeted therapies, immunotherapy, and supportive care continue to shape breast cancer management. For eligible individuals, Metastatic breast cancer clinical trials may also offer opportunities to contribute to medical knowledge and explore investigational approaches.